Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada)

The Latest

New Option for PrEP: TAF/FTC Is Non-Inferior to TDF/FTC -- Results of Phase 3 DISCOVER Study

The results from this large study are notable, showing that a new version of PrEP is at least as affective at protecting against HIV infection as the currently approved formulation.

By Simon Collins for HIV i-Base

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

By Martha Kempner

This Week in HIV Research: Where Are the Cervical Cancer Screens?

Poor rates of cervical cancer screening for women of color; interest vs. action among potential organ donors; an online depression intervention; Truvada levels in men’s vs. women’s hair.

By Barbara Jungwirth and Myles Helfand

No Increase in Adverse Birth Outcomes With Maternal TDF/FTC in U.S. Study

Among pregnant women with HIV in the PROMISE trial, use of TDF/FTC/LPV/r was not associated with increased risk of adverse infant birth outcomes when compared to AZT/3TC/LPV/r or TDF/FTC/ATV/r.

By Polly Clayden for HIV i-Base

First Generic TDF/FTC Approved in EU

The European Medicines Agenecy has noted a positive summary of opinion for the first generic combination of tenofovir/emtricitabine (Truvada).

By Simon Collins for HIV i-Base

HIV Drug Development Pipeline Update, Fall 2014 Edition

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.

By Myles Helfand

Significantly Less BMD Loss With HIV Therapy That Doesn't Contain Tenofovir/Emtricitabine

Raltegravir was associated with significantly less bone mineral density (BMD) loss in the hip and lumbar spine than was tenofovir/emtricitabine when used as part of a first-line antiretroviral therapy regimen that contained darunavir boosted with rit...

By Theo Smart

PrEP Needs a Week to Offer Full Protection; Efficacy Lingers for Several Days

Pharmacokinetic analysis informs estimates of how long it takes for PrEP to reach protective levels, and how long individuals would remain protected if they stop PrEP.

By JD Davids

Uptake of PrEP in the United States

Pre-exposure prophylaxis, or PrEP, is an exciting new HIV prevention strategy that involves the ongoing use of anti-HIV drugs by an HIV-negative person in order to reduce their risk of becoming infected with HIV. Many types of PrEP are currently bein...

By James Wilton for Canadian AIDS Treatment Information Exchange

Taking PrEP Does Not Increase Drug Resistance Risk

With the recent U.S. Centers for Disease Control and Prevention's guidelines recommending pre-exposure prophylaxis (PrEP) for individuals in groups at high risk for HIV, there has been some concern over the possibility of developing drug resistance i...

By Warren Tong